The cost and value of cancer medicines in Ontario, Canada
Lancet Oncol
.
2024 Apr;25(4):412-413.
doi: 10.1016/S1470-2045(24)00099-8.
Author
Christopher J Longo
1
Affiliation
1
Health Policy and Management, DeGroote School of Business, McMaster University, Burlington L7L 5R8, ON, Canada. Electronic address: cjlongo@mcmaster.ca.
PMID:
38547886
DOI:
10.1016/S1470-2045(24)00099-8
No abstract available
MeSH terms
Canada
Cost-Benefit Analysis
Humans
Neoplasms* / drug therapy
Neoplasms* / epidemiology
Ontario